Reinert, Tomás
Gonçalves, Rodrigo
Ellis, Matthew J.
Article History
First Online: 16 April 2018
Compliance with Ethical Standards
:
: Tomás Reinert has received research funding from AstraZeneca and has received speaker’s honoraria from AstraZeneca, Novartis, and Pfizer.Rodrigo Gonçalves declares that he has no conflict of interest.Matthew J. Ellis has received clinical trial support from Novartis (P024 and Z1031 trials) and Pfizer (Z1031 trial); has received compensation from AstraZeneca, Pfizer, and Novartis for service as a consultant; and has licensed PAM50 patents to NanoString for Prosigna®. The commercial version of PAM50 is not mentioned within this article.
: Dr Ellis performed the Preoperative Letrozole Study and the Z1031 Study. He was a coinvestigator of the P024 Study. All these studies on human subjects were approved by the relevant ethics committees as outlined in the publications cited.